What's New in Imaging for Gynecologic Cancer?

Curr Oncol Rep. 2017 Nov 6;19(12):85. doi: 10.1007/s11912-017-0640-3.


Magnetic resonance imaging (MRI) is the optimal modality for local staging of gynecological tumors. Advances in functional MRI with diffusion-weighted and dynamic contrast-enhanced sequences provide more detailed information regarding tumor cellularity, vascularity, and viability. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) now has an established role in imaging for gynecological cancers, particularly staging of locally advanced cervical cancers and pre-salvage exenterative therapy in relapsed gynecologic tumors. Novel PET tracers, targeting other aspects of tumor biology, are being evaluated although none are currently in routine clinical use. New PET/MR scanners have the potential to combine the strengths of both modalities in one sitting. This review covers advances in gynecologic imaging concentrating on cervical, endometrial, and ovarian cancers.

Keywords: Diffusion-weighted imaging (DWI); Dynamic contrast enhanced MRI (DCE-MRI); Functional imaging; Magnetic resonance imaging (MRI); PET/MR; Positron emission tomography/computed tomography (PET/CT).

Publication types

  • Review

MeSH terms

  • Diffusion Magnetic Resonance Imaging / trends
  • Female
  • Fluorodeoxyglucose F18 / therapeutic use
  • Genital Neoplasms, Female / diagnosis*
  • Genital Neoplasms, Female / diagnostic imaging*
  • Genital Neoplasms, Female / pathology
  • Humans
  • Magnetic Resonance Imaging / trends
  • Multimodal Imaging / trends*
  • Positron Emission Tomography Computed Tomography / trends
  • Radiopharmaceuticals / therapeutic use


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18